nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

03.10.2023 | Research

Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation

verfasst von: Junzheng Zhang, Lu Song, Guanrong Li, Anqi Liang, Xiaoting Cai, Yaqi Huang, Xiao Zhu, Xiaorong Zhou

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 19/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer, and comprehending its molecular mechanisms is pivotal for advancing treatment efficacy. This study aims to explore the prognostic and functional significance of base excision repair (BER)-related long non-coding RNAs (BERLncs) in LUAD.

Methods

A risk score model for BERLncs was developed using the least absolute shrinkage and selection operator regression and Cox regression analysis. Model validation and prognostic evaluation were performed using Kaplan–Meier and receiver-operating characteristic curve analyses. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted to elucidate the potential biological functions of BERLncs. Comparative analyses were carried out to investigate disparities in tumor mutation burden (TMB), immune infiltration, tumor immune dysfunction and exclusion (TIDE) score, chemosensitivity, and immune checkpoint gene expression between the two risk groups.

Results

A predictive risk score model comprising 19 BERLncs was successfully developed. Patients were divided into high-risk and low-risk groups according to the median risk score. The high-risk subgroup exhibited significantly inferior overall survival. Functional enrichment analysis revealed pathways associated with lung cancer development, notably the neuroactive ligand–receptor interaction pathway. High-risk patients demonstrated elevated TMB, diminished TIDE scores, and an immunosuppressive tumor microenvironment, while low-risk patients displayed potential benefits from immunotherapy. Additionally, the risk model identified potential anticancer agents.

Conclusion

The risk score model based on BERLncs shows promise as a prognostic biomarker for LUAD patients, providing valuable insights for clinical decision-making, therapeutic strategies, and understanding of underlying biological mechanisms.

Nur mit Berechtigung zugänglich

Almeida KH, Sobol RW (2007) A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (amst) 6:695–711. https://doi.org/10.1016/j.dnarep.2007.01.009CrossRefPubMed

Babukov Y, Aleksandrov R, Ivanova A, Atemin A, Stoynov S (2021) DNArepairK: an interactive database for exploring the impact of anticancer drugs onto the dynamics of DNA repair proteins. Biomedicines. https://doi.org/10.3390/biomedicines9091238CrossRefPubMedPubMedCentral

Bahjat M, Guikema JEJ (2017) The complex interplay between DNA injury and repair in enzymatically induced mutagenesis and DNA damage in B lymphocytes. Int J Mol Sci. https://doi.org/10.3390/ijms18091876CrossRefPubMedPubMedCentral

Brueckl WM, Ficker JH, Zeitler G (2020) Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer 20:1185. https://doi.org/10.1186/s12885-020-07690-8CrossRefPubMedPubMedCentral

Chandra Gupta S, Nandan Tripathi Y (2017) Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer 140:1955–1967. https://doi.org/10.1002/ijc.30546CrossRefPubMed

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867. https://doi.org/10.1038/nature01322CrossRefPubMedPubMedCentral

Denton AE, Roberts EW, Fearon DT (2018) Stromal cells in the tumor microenvironment. Adv Exp Med Biol 1060:99–114. https://doi.org/10.1007/978-3-319-78127-3_6CrossRefPubMed

Dong Z, Liu H, Zhao G (2020) Long noncoding RNA SNHG6 promotes proliferation and inhibits apoptosis in non-small cell lung cancer cells by regulating miR-490–3p/RSF1 axis. Cancer Biother Radiopharm 35:351–361. https://doi.org/10.1089/cbr.2019.3120CrossRefPubMed

Endris V, Buchhalter I, Allgauer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O et al (2019) Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer 144:2303–2312. https://doi.org/10.1002/ijc.32002CrossRefPubMed

Finotello F, Trajanoski Z (2018) Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol Immunother 67:1031–1040. https://doi.org/10.1007/s00262-018-2150-zCrossRefPubMedPubMedCentral

Gao N, Li Y, Li J, Gao Z, Yang Z, Li Y, Liu H, Fan T (2020) Long non-coding RNAs: the regulatory mechanisms, research strategies, and future directions in cancers. Front Oncol 10:598817. https://doi.org/10.3389/fonc.2020.598817CrossRefPubMedPubMedCentral

Geeleher P, Cox N, Huang RS (2014) pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE 9:e107468. https://doi.org/10.1371/journal.pone.0107468CrossRefPubMedPubMedCentral

Guo S, Zhu X, Huang Z, Wei C, Yu J, Zhang L, Feng J, Li M, Li Z (2023) Genomic instability drives tumorigenesis and metastasis and its implications for cancer therapy. Biomed Pharmacother 157:114036. https://doi.org/10.1016/j.biopha.2022.114036CrossRefPubMed

Hattar K, Reinert CP, Sibelius U, Gokyildirim MY, Subtil FSB, Wilhelm J, Eul B, Dahlem G, Grimminger F, Seeger W et al (2017) Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro. Cancer Immunol Immunother 66:799–809. https://doi.org/10.1007/s00262-017-1980-4CrossRefPubMedPubMedCentral

Hou S, Xu H, Liu S, Yang B, Li L, Zhao H, Jiang C (2022) Integrated bioinformatics analysis identifies a new stemness index-related survival model for prognostic prediction in lung adenocarcinoma. Front Genet 13:860268. https://doi.org/10.3389/fgene.2022.860268CrossRefPubMedPubMedCentral

Hu J, Wang T, Chen Q (2019) Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma. Transl Cancer Res 8:1046–1064. https://doi.org/10.21037/tcr.2019.06.09CrossRefPubMedPubMedCentral

Jian D, Li XM, Dai N, Liang DD, Zhang G, Mao CY, Wang D, Song GB, Li MX, Luo H (2022) Inhibition of APE1 expression enhances the antitumor activity of olaparib in triple-negative breast cancer. Evid Based Complement Alternat Med 2022:6048017. https://doi.org/10.1155/2022/6048017CrossRefPubMedPubMedCentral

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24:1550–1558. https://doi.org/10.1038/s41591-018-0136-1CrossRefPubMedPubMedCentral

Jiao Y, Kang G, Pan P, Fan H, Li Q, Li X, Li J, Wang Y, Jia Y, Zhang L et al (2023) Acetylcholine promotes chronic stress-induced lung adenocarcinoma progression via alpha5-nAChR/FHIT pathway. Cell Mol Life Sci 80:119. https://doi.org/10.1007/s00018-023-04742-7CrossRefPubMed

Li S, Zhang Z, Lai WF, Cui L, Zhu X (2020) How to overcome the side effects of tumor immunotherapy. Biomed Pharmacother 130:110639. https://doi.org/10.1016/j.biopha.2020.110639CrossRefPubMed

Li Y, Yi Y, Lv J, Gao X, Yu Y, Babu SS, Bruno I, Zhao D, Xia B, Peng W et al (2023) Low RNA stability signifies increased post-transcriptional regulation of cell identity genes. Nucl Acids Res. https://doi.org/10.1093/nar/gkad300CrossRefPubMedPubMedCentral

Lin Q, Zhang M, Kong Y, Huang Z, Zou Z, Xiong Z, Xie X, Cao Z, Situ W, Dong J et al (2023) Risk score = LncRNAs associated with doxorubicin metabolism can be used as molecular markers for immune microenvironment and immunotherapy in non-small cell lung cancer. Heliyon 9:e13811. https://doi.org/10.1016/j.heliyon.2023.e13811CrossRefPubMedPubMedCentral

Liu J, Liu Q, Shen H, Liu Y, Wang Y, Wang G, Du J (2022) Identification and validation of a three pyroptosis-related lncRNA signature for prognosis prediction in lung adenocarcinoma. Front Genet 13:838624. https://doi.org/10.3389/fgene.2022.838624CrossRefPubMedPubMedCentral

Maleki Vareki S (2018) High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 6:157. https://doi.org/10.1186/s40425-018-0479-7CrossRefPubMedPubMedCentral

Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kaminska B, Huelsken J, Omberg L, Gevaert O et al (2018) Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173:338-354 e315. https://doi.org/10.1016/j.cell.2018.03.034CrossRefPubMedPubMedCentral

Meng Z, Zhang R, Wu X, Zhang M, Jin T (2022) PD-L1 mediates triple-negative breast cancer evolution via the regulation of TAM/M2 polarization. Int J Oncol. https://doi.org/10.3892/ijo.2022.5440CrossRefPubMedPubMedCentral

Milanowska K, Krwawicz J, Papaj G, Kosinski J, Poleszak K, Lesiak J, Osinska E, Rother K, Bujnicki JM (2011) REPAIRtoire—a database of DNA repair pathways. Nucl Acids Res 39:D788-792. https://doi.org/10.1093/nar/gkq1087CrossRefPubMed

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558–562. https://doi.org/10.1038/nature13904CrossRefPubMed

Roy S, Lu K, Nayak MK, Bhuniya A, Ghosh T, Kundu S, Ghosh S, Baral R, Dasgupta PS, Basu S (2017) Activation of D2 dopamine receptors in CD133+ve cancer stem cells in non-small cell lung carcinoma inhibits proliferation, clonogenic ability, and invasiveness of these cells. J Biol Chem 292:435–445. https://doi.org/10.1074/jbc.M116.748970CrossRefPubMed

Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H et al (2010) GeneCards Version 3: the human gene integrator. Database (oxford) 2010:baq020. https://doi.org/10.1093/database/baq020CrossRefPubMed

Shinmura K, Goto M, Suzuki M, Tao H, Yamada H, Igarashi H, Matsuura S, Maeda M, Konno H, Matsuda T et al (2011) Reduced expression of MUTYH with suppressive activity against mutations caused by 8-hydroxyguanine is a novel predictor of a poor prognosis in human gastric cancer. J Pathol 225:414–423. https://doi.org/10.1002/path.2953CrossRefPubMed

Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763CrossRefPubMed

Sweasy JB, Lang T, DiMaio D (2006) Is base excision repair a tumor suppressor mechanism? Cell Cycle 5:250–259. https://doi.org/10.4161/cc.5.3.2414CrossRefPubMed

Tan S, Li D, Zhu X (2020) Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother 124:109821. https://doi.org/10.1016/j.biopha.2020.109821CrossRefPubMed

Tan S, Li Z, Li K, Li Y, Liang G, Tang Z, Kang J, Chen W, Li M, Zou Z et al (2021) The regulators associated with N6-methyladenosine in lung adenocarcinoma and lung squamous cell carcinoma reveal new clinical and prognostic markers. Front Cell Dev Biol 9:741521. https://doi.org/10.3389/fcell.2021.741521CrossRefPubMedPubMedCentral

Wallace SS, Murphy DL, Sweasy JB (2012) Base excision repair and cancer. Cancer Lett 327:73–89. https://doi.org/10.1016/j.canlet.2011.12.038CrossRefPubMedPubMedCentral

Wan R, Liao H, Liu J, Zhou L, Yin Y, Mu T, Wei J (2022) Development of a 5-gene signature to evaluate lung adenocarcinoma prognosis based on the features of cancer stem cells. Biomed Res Int 2022:4404406. https://doi.org/10.1155/2022/4404406CrossRefPubMedPubMedCentral

Wei W, Liu C, Wang M, Jiang W, Wang C, Zhang S (2022) Prognostic signature and tumor immune landscape of N7-methylguanosine-related lncRNAs in hepatocellular carcinoma. Front Genet 13:906496. https://doi.org/10.3389/fgene.2022.906496CrossRefPubMedPubMedCentral

Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes. Science 291:1284–1289. https://doi.org/10.1126/science.1056154CrossRefPubMed

Wu Z, Li S, Zhu X (2021) The mechanism of stimulating and mobilizing the immune system enhancing the anti-tumor immunity. Front Immunol 12:682435. https://doi.org/10.3389/fimmu.2021.682435CrossRefPubMedPubMedCentral

Xie S, Wu Z, Qi Y, Wu B, Zhu X (2021) The metastasizing mechanisms of lung cancer: recent advances and therapeutic challenges. Biomed Pharmacother 138:111450. https://doi.org/10.1016/j.biopha.2021.111450CrossRefPubMed

Xiong Z, Han Z, Pan W, Zhu X, Liu C (2023) Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer. PLoS ONE 18:e0286122. https://doi.org/10.1371/journal.pone.0286122CrossRefPubMedPubMedCentral

Xu Y, Tao T, Li S, Tan S, Liu H, Zhu X (2022) Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma. Front Genet 13:975905. https://doi.org/10.3389/fgene.2022.975905CrossRefPubMedPubMedCentral

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T et al (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572–576. https://doi.org/10.1038/nature14001CrossRefPubMed

Ye Z, Huang Y, Ke J, Zhu X, Leng S, Luo H (2021) Breakthrough in targeted therapy for non-small cell lung cancer. Biomed Pharmacother 133:111079. https://doi.org/10.1016/j.biopha.2020.111079CrossRefPubMed

Ye W, Wu Z, Gao P, Kang J, Xu Y, Wei C, Zhang M, Zhu X (2022) Identified gefitinib metabolism-related lncRNAs can be applied to predict prognosis, tumor microenvironment, and drug sensitivity in non-small cell lung cancer. Front Oncol 12:939021. https://doi.org/10.3389/fonc.2022.939021CrossRefPubMedPubMedCentral

Zhang W, Ke Y, Liu X, Jin M, Huang G (2022) Drug resistance in NSCLC is associated with tumor micro-environment. Reprod Biol 22:100680. https://doi.org/10.1016/j.repbio.2022.100680CrossRefPubMed

Zhang W, Wei C, Huang F, Huang W, Xu X, Zhu X (2023) A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses. Front Oncol 13:1104137. https://doi.org/10.3389/fonc.2023.1104137CrossRefPubMedPubMedCentral

Zhong Y, Li M, Guo S, Li M, Cao Z, Luo X, Liu J, Liang R, Shao Y, Yang Y et al (2023) Histone deacetylase 1 expression and regulatory network in lung adenocarcinoma based on data mining and implications for targeted treatment. J Oncol 2023:2745074. https://doi.org/10.1155/2023/2745074CrossRefPubMedPubMedCentral

Titel: Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation
verfasst von: Junzheng Zhang
Lu Song
Guanrong Li
Anqi Liang
Xiaoting Cai
Yaqi Huang
Xiao Zhu
Xiaorong Zhou
Publikationsdatum: 03.10.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 19/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05435-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 19/2023

Potential value of mitochondrial regulatory pathways in the clinical application of clear cell renal cell carcinoma: a machine learning-based study

Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors

The value of an apparent diffusion coefficient histogram model in predicting meningioma recurrence

Principles of oncology taught in a one-week course

Transanal local excision versus intersphincteric resection for low rectal cancer with stage ypT0-1ycN0 after neoadjuvant chemoradiotherapy: an inverse probability weighting analysis for oncological and functional outcomes

Using machine learning to identify patients at high risk of developing low bone density or osteoporosis after gastrectomy: a 10-year multicenter retrospective analysis

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie